HC Wainwright Has Positive Estimate for ORIC Q3 Earnings

Key Points

• HC Wainwright has revised its Q3 2025 earnings estimate for Oric Pharmaceuticals to ($0.38) per share, reflecting an improvement from a previous estimate of ($0.46).
• The company's stock currently holds an average rating of "Moderate Buy" with a consensus price target of $17.63.
• Oric Pharmaceuticals' shares have recently seen significant institutional investment, with 95.05% of the stock owned by institutional investors.

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC - Free Report) - HC Wainwright lifted their Q3 2025 EPS estimates for Oric Pharmaceuticals in a note issued to investors on Thursday, August 14th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($0.38) for the quarter, up from their prior forecast of ($0.46). HC Wainwright currently has a "Buy" rating and a $19.00 target price on the stock. The consensus estimate for Oric Pharmaceuticals' current full-year earnings is ($2.17) per share. HC Wainwright also issued estimates for Oric Pharmaceuticals' Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.60) EPS, Q1 2026 earnings at ($0.37) EPS, Q2 2026 earnings at ($0.36) EPS, Q3 2026 earnings at ($0.38) EPS, Q4 2026 earnings at ($0.40) EPS and FY2026 earnings at ($1.51) EPS.

ORIC has been the subject of a number of other research reports. JPMorgan Chase & Co. dropped their price target on shares of Oric Pharmaceuticals from $20.00 to $17.00 and set an "overweight" rating for the company in a research note on Thursday, August 14th. Wedbush restated an "outperform" rating and issued a $20.00 price target on shares of Oric Pharmaceuticals in a research note on Monday, June 23rd. Guggenheim restated a "buy" rating and issued a $18.00 price target on shares of Oric Pharmaceuticals in a research note on Wednesday, August 13th. Oppenheimer dropped their price target on shares of Oric Pharmaceuticals from $15.00 to $12.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. Finally, Cantor Fitzgerald restated an "overweight" rating on shares of Oric Pharmaceuticals in a research note on Tuesday, May 6th. Nine research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Oric Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $17.63.

Oric Pharmaceuticals Price Performance

Shares of NASDAQ:ORIC traded up $0.05 during midday trading on Monday, reaching $9.74. The company had a trading volume of 531,437 shares, compared to its average volume of 1,319,945. The stock's fifty day moving average price is $10.30 and its 200-day moving average price is $8.07. The stock has a market capitalization of $945.95 million, a P/E ratio of -5.15 and a beta of 1.69. Oric Pharmaceuticals has a one year low of $3.90 and a one year high of $14.67.

Oric Pharmaceuticals (NASDAQ:ORIC - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.01).

Institutional Trading of Oric Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE raised its position in Oric Pharmaceuticals by 34.0% during the fourth quarter. Bank of America Corp DE now owns 112,520 shares of the company's stock valued at $908,000 after acquiring an additional 28,570 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Oric Pharmaceuticals by 16.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 717,188 shares of the company's stock worth $5,788,000 after acquiring an additional 103,237 shares during the last quarter. Vivo Capital LLC grew its stake in shares of Oric Pharmaceuticals by 62.8% in the first quarter. Vivo Capital LLC now owns 2,080,450 shares of the company's stock worth $11,609,000 after acquiring an additional 802,632 shares during the last quarter. Sphera Funds Management LTD. boosted its stake in Oric Pharmaceuticals by 112.8% during the fourth quarter. Sphera Funds Management LTD. now owns 273,213 shares of the company's stock worth $2,205,000 after buying an additional 144,817 shares in the last quarter. Finally, Diadema Partners LP acquired a new stake in Oric Pharmaceuticals during the fourth quarter worth $1,729,000. 95.05% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Oric Pharmaceuticals news, CFO Dominic Piscitelli sold 32,466 shares of the firm's stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $10.50, for a total value of $340,893.00. Following the completion of the transaction, the chief financial officer directly owned 68,317 shares in the company, valued at $717,328.50. This trade represents a 32.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Angie You bought 26,597 shares of the firm's stock in a transaction on Friday, June 20th. The stock was purchased at an average price of $9.39 per share, with a total value of $249,745.83. Following the completion of the acquisition, the director owned 26,597 shares of the company's stock, valued at approximately $249,745.83. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 40,000 shares of company stock valued at $416,289. Corporate insiders own 6.82% of the company's stock.

Oric Pharmaceuticals Company Profile

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.